Coco C. Dekkers
Utrecht, UT, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Current treatment landscape of atopic dermatitis focusing on real-world evidence of dupilumab treatment.
Journal: Expert opinion on biological therapy
Published: December 01, 2025
Impact of Dupilumab and Upadacitinib Treatment on Epigenetic and Transcriptomic Alterations in Skin-Homing T Cells of Atopic Dermatitis Patients.
Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
Published: May 06, 2025
Measurement of Tralokinumab Concentrations in Serum and Tear Fluid of Atopic Dermatitis Patients and the Relationship With Treatment Response and Ocular Surface Disease.
Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
Published: February 23, 2025
Type 2 Immune-Dominant Endotype Is Not Associated With Increased Responsiveness to Dupilumab Treatment in Adult Atopic Dermatitis Patients.
Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
Published: July 03, 2024
The pleiotropic role of interleukin-13 in the pathogenesis of atopic dermatitis.
Journal: The British journal of dermatology
Published: April 17, 2024
Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28-Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels.
Journal: Allergy
Published: March 08, 2024
Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry.
Journal: Journal of the American Academy of Dermatology
Published: July 26, 2023
IgE levels in patients with atopic dermatitis steadily decrease during treatment with dupilumab regardless of dose interval.
Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
Published: June 20, 2023
Limited excretion of dupilumab into breastmilk: A case report.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: January 30, 2023
Switching from dupilumab to tralokinumab in atopic dermatitis patients with ocular surface disease: Preliminary case series.
Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
Published: January 11, 2023
Biological Tipping Point in Patients with Atopic Dermatitis Treated with Different Dosing Intervals of Dupilumab.
Journal: The Journal of investigative dermatology
Published: December 14, 2022
Last Updated: 09/26/2026